Atty. Dkt. No. 074129-0510

N RHE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Shigeru Kamei et al.

Title:

SUSTAINED-RELEASE PREPARATION

Appl. No.:

10/025,967

Filing Date:

12/26/2001

Examiner:

D. Lukton

Art Unit:

1653

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

06/20/2005 SDENBOB1 00000035 10025967

01 FC:1806

180.00 OP

RELEVANCE OF EACH DOCUMENT

The documents are either in English or are presented with an English abstract or partial translation. English translations of the foreign-language documents are not readily available. However, the absence of such translation does not relieve the PTO from its duty to consider the submitted foreign language documents (37 CFR §1.98 and MPEP §609). English-language abstracts are attached.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A fee in connection with submission of an information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date June 17, 2005

FOLEY & LARDNER LLP Customer Number: 22428 Telephone:

Facsimile:

(202) 672-5569 (202) 672-5399 Matthew E. Mulkeen Attorney for Applicants Registration No. 44,250 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

number.	i)					0.6
	Substitute for	form 1449B	/PTO		0	
	INFORMATIO	N DISCLO	SURE	Application Number	10/025,967	
	STATEMENT	BY APPLI	CANT	Filing Date	12/26/2001	7 2005 4
	Date Submitte	d: June 17	7 2005	First Named Inventor	Shigeru Kamei	D JUN 1 FOOT S
	Date Submitte	u. Julie i i	, 2003	Group Art Unit	Unassigned	E 8
	(use as many sh	eets as ne	cessary)	Examiner Name	Unassigned	Mr. at
Sheet	1	of	5	Attorney Docket Number	074129-0510	RADENAGE

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	U.S. Patent Number	Document Kind Code ² (if	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant			
]	Number	known)		IVIIVI-DD-1111	Figures Appear			
	A1	1,995,970		DOROUGH	03/35				
	A2	2,362,511		TEETERS	11/44				
	A3	2,438,208		FLLACHIONE et al.	03/48				
	A4	2,703,316		SCHNEIDER et al.	03/55				
	A5	2,758,987		SAIZBERG	08/56				
	A6	3,043,782		JENSEN	07/62				
	A7	3,092,553		FISHER et al.	06/63				
	A8	3,297,033		SCHMITT et al.	01/67				
	A9	3,523,906		VRANCKEN et al.	08/70				
	A10	3,539,465		HIESTAND et al.	11/70				
	A11	3,565,869		DePROSPERO	02/71				
	A12	3,636,956		SCHNEIDER	01/72	·			
	A13	3,645,911		van BESAUW et al.	02/72				
~	A14	3,691,090		KITAJIMA et al.	09/72				
	A15	3,755,553		SCRIBNER et al.	08/73				
	A16	3,755,558		SCRIBNER	08/73				
	A17 A18	3,839,297		WASSERMAN et al. BONCEY	10/75 05/75				
	A19	3,882,228 3,890,283		CASEY et al.	06/75				
	A20	3,912,692		CASEY et al.	10/75				
	A21	3,922,338		ESTEVENEL et al.	11/75				
	A22	3,956,172		SAEKI et al.	05/76				
	A23	4,137,921		OKUZUMI et al.	02/79				
	A24	4,234,571		NESTOR et al.	11/80				
 .	A25	4,249,531		HELLER et al.	02/81				
	ļ	· · · · · · · · · · · · · · · · · · ·			06/81				
	A26	4,272,398		JAFFE		The same of the sa			
	A27	4,273,920		NEVIN	06/81				
	A28	4,384,975		FONG	05/83				
	A29	4,389,330		TICE et al.	06/83				
	A30	4,479,911		FONG	10/84				
	A31	4,555,399		HSIAO	11/85				
	A32	4,605,730		SHALABY et al.	08/86				
	A33	4,622,244		LAPKA et al.	11/86				
	A34	4,637,905		GARDNER	01/87				
	A35	4,652,441		OKADA et al.	03/87				
	A36	4,667,191		TANAKA et al.	06/87				
		4,710,384		ROTMAN	12/87				
	A38	4,728,721		YAMAMOTO et al.	03/88				
	A39	4,849,228		YAMAMOTO et al.	07/89				

Date
Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.^t u

	Substitute for	or form 1449B/	PTO	Complete if Known		
	INFORMATI	ON DISCLOS	SURE	Application Number	10/025,967	4
	STATEMEN	T BY APPLIC	CANT	Filing Date	12/26/2001	28/
	Data Submit	ted: June 17	2005	First Named Inventor	Shigeru Kamei	m 1 7 2005 H
	Date Submit	lea. Julie 17	, 2005	Group Art Unit	Unassigned v J	M T Jan G
	(use as many s	sheets as nec	cessary)	Examiner Name	Unassigned 🖔	9
Sheet	2	of	5	Attorney Docket Number	074129-0510	AEIL

	U.S. Patent Document			
A40	4,917,893	OKADA et al.	04/90	
A41	4,954,298	YAMAMOTO et al.	09/90	
A42	5,330,767	YAMAMOTO et al.	07/94	
A43	5,480,656	OKADA et al.	01/96	
A44	5,575,987	KAMEI et al.	11/96	
A45	5,631,020	OKADA et al.	05/97	
A46	5,643,607	OKADA et al.	07/97	
A47	5,716,640	KAMEI et al.	02/98	
A48	5,972,891	KAMEI et a.	10/99	
A49	6,528,093	KAMEI et al.	03/2003	

				F	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. ¹	Office	oreign Patent D ³ Number ⁴	ocument Kind Code ⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]
	A50	CA	1 169 090		IMPERIAL CHEMICAL INDUSTRIES PLC	02/1982		
	A51	EP	0 107 591	A2	UNITED STATES SURGICAL CORPORATION	05/1984		
	A52	EP	0 145 240	A2	TAKEDA CHEMICAL INDUSTRIES LTD.	06/1985		
	A53	EP	0 178 824	A1	TAKEDA CHEMICAL INDUSTRIES LTD.	04/1986		
	A54	FR	2,551,072		SANDOZ-ERFINDUNGEN	08/1984		ABS.
	A55	FR	2,126,270		DU PONT DE NEMOURS & CO.	02/1972		ABS.
	A56	JP	40-500		FUJI PHOTO FILM CO. LTD.	01/1965	Eng. Translation of Detailed Description, Example 1 and Claim	PART.
	A57	JP	43-3017		DASERU LTD.	02/1968	Eng. Translation of First Three Paragraphs and Claim 1	PART.
	A58	JP	55-114193		HITACHI LTD.	05/1972		ABS.
	A59	UK	1,351,409		SCRIBNER	02/72		
	A60	UK	1,405, 108		DE JAEGER ET AL.	12/71		Ì
	A61	UK	2,145,422 A		SANDOZ LTD.	08/84		
	A62	UK	2,246,514 A		SOCIETE DE CONSILIS DE RECHERCHES ET D' APPLICATIONS SCIENTIFQUES	05/92		

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

lumber.	Substitute for fe	orm 1449B	/PTO		Complete if Known	CIPE
	INFORMATION			Application Number	10/025,967	
	STATEMENT I			Filing Date	12/26/2001	2000
	Data Cubasittad	li luna 15	7 2005	First Named Inventor	Shigeru Kamei	2 JUN 1 7 2005 3
Date Submitted: June 17, 2005				Group Art Unit	Unassigned	Ž, J
	(use as many she	eets as ne	cessary)	Examiner Name	Unassigned	49
Sheet	3	of	5	Attorney Docket Number	074129-0510	RADEMAR

				F	DREIGN PATENT DOCUMEN	TS		•
Examiner Initials*	Cite No. ¹	F Office	MIIMINEL	ent Code ⁵ (nown)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]
	A63	UK	929,402			11/59		
	A64	wo	89/04673		BOARD OF REGENTS OF THE UNIV. OF TEXAS SYSTEM	06/89	•	
	A65	wo	98/35654		OAKWOOD LABORATORIES LLC.	09/98		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A66	ARSHADY,R., "Preparation of biodegradable microspheres and microcapsules: 2. Polyactides and related Polyesters," <u>Journal of Controlled Release</u> , Vol. 17, pp. 1-20, 1991	
	A67	BAKAN, J. A. et al., "Microencapsulation," <u>The Theory and Practice of Industrial Pharmacy</u> , pp. 384-407, 1970	
	A68	CHANG, T., "Biodegradable Semipermeable Microcapsules containing Enzymes, Hormones, Vaccines, and Other Biologicals," <u>Journal of Bioengineering</u> , 1:25-31, 1976	
	A69	DRESSLER, et al., "Viable Prosthetic Interface," <u>J. Biomed. Mater, Res. Sympomium</u> 1:169-178 (1971)	
	A70	Journal of the Chemical Society of Japan, Industrial Chemistry Section, Volume 72, 1969 pp. 493-499 (English Translation of Sections 2.1 and 3.1)	
	A71	Journal of the Chemical Society of Japan, Industrial Chemistry Section, 68(5), English Abstracts, A52-A53, pp. 983-986 (Japanese Text), 1965	
	A72	KEIPERT, S. et al., "Antiglaumakotosahaltige Ophthalmika mit prolongierter Wirkung auf Basis makromolekularer Hilfsstoffe," <u>Die Pharmazie</u> , pp. 594-595 (English Abstract at page 594), August 1990	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number "

	Substitute for form 1449B/PTO		Complete if Known	OIPE
	INFORMATION DISCLOSUR	Application Number	10/025,967	6
	STATEMENT BY APPLICAN	Filing Date	12/26/2001	
	Data Submitted: June 17 200	First Named Inventor	Shigeru Kamei	JUN 1 7 2005
	Date Submitted: June 17, 200	Group Art Unit	Unassigned	3
	(use as many sheets as necess	ry) Examiner Name	Unassigned	E 19
Sheet	4 of 5	Attorney Docket Number	er 074129-0510	RADEMARI

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶			
	A73	KONDO, A., Microcapsule Processing and Technology, Marcel Dekker, Inc., New York, New York (1979), Chapter I, "Microcapsules – General Concepts," pp. 1-10; Chapter III, "Applications and Studies of Microcapsules," pp. 18-26; Chapter IV, "History and Classification of Microencapsulation," pp. 27-34; Chapter X, "Microencapsulation Utilizing In-Liquid Drying Process (Complex Emulsion Method)," pp. 106-120				
	A74	KULKARNI et al, "Biodegradable Poly(lactic acid) Polymers," <u>Journal of Biomedical Materials Research,</u> 5:169-181, 1971				
	A75	KULKARNI et al, "Polyactic Acid for Surgical Implants," <u>Archives of Surgery</u> , 93(5):839-843, November 1966				
	A76	LEWIS, D. et al., "Controlled Release of Bioactive Agents from Lactide/Glycolide Polymers," <u>Biodegradable Polymers as Drug Delivery Systems</u> , pp. 1-41, 1990				
	A77	Microcapsule, Industrial Technology, Library 25, pages 102 (1971)				
	A78	OGAWA, Y. et al, "Controlled Release of LHRH Agonist, Leuprolide Acetate, from Microcapsules: Serum Drug Level Profiles and Pharmacological Effects in Animals," J. Pharma Pharmacol., PP. 439-444, 1989				
	A79	OGAWA et al., "A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly (lactic/glycolic) acid." Chem. Pharm. Bull., Vol. 36, No. 3, pp. 1095-1103, 1988.				
	A80	OKADA, H. et al., "One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate," Advanced Drug Delivery Reviews, 28:43-70, 1997	ì			
	A81	OKADA, H. et al., "One-month release injectable microspheres of leuprolide acetate inhibit steroidogenesis and genital organ growth in rats," <u>International Journal of Pharmaceutics</u> , 54:231-239, 1989				
	A82	OKADA, H. et al., Critical Reviews in Therapeutic Drug Carrier Systems, 12(1):1-99, 1995				
	A83	OMELCZUK, M. et al, "The Influence of Polymer Glass Transition Temperature and Molecular Weight on Drug Release from Tablets Containing Poly(DL-lactic Acid)," Pharmaceutical Research, Vol. 9, No. 1, pp. 26-32, January 1992				
	A84	OMELCZUK, M. et al., "Effect of Thermal Treatment on the Physical-Mechanical and Dissolution Properties of Compacts Containing Biodegradable Polymers," <u>Proceedings of the Ninth International Pharmacuetial Technology Conference</u> Veldhoven, the Netherlands, 1:28-44 (1990)				
	A85	OMELCZUK, M. et al., "The Influence of Thermal Treatment on the Physical-Mechanical and Dissolution Properties of Tablets Containing Poly(DL-Lactic Acid)," Pharmaceutical Research 10(4):542-548 (1993)				

Date
Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for	or form 1449B	/PTO	Complete if Known			
	INFORMATI	ON DISCLO	SURE	Application Number	10/025,967	CIPE	
STATEMENT BY APPLICANT				Filing Date	12/26/2001 /	18	
	Data Submitted: June 17, 2005			First Named Inventor	Shigeru Kamei /	8	
Date Submitted: June 17, 2005 (use as many sheets as necessary)				Group Art Unit	Unassigned	uu 1 7 2005 H	
				Examiner Name	Unassigned	THE THE	
Sheet	5	of	5	Attorney Docket Number	074129-0510	in 3	

	PACEMEN	
	NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [€]
A86	PITT, C. et al, "Sustained Drug Delivery Systems, 1. The Permeability of Poly(e-Caprolactone), Poly(DL-Lactic Acid), and Their Copolymers," <u>Journal of Biomedical Materials Research</u> , Vol. 13, pp. 418-507, 1979	
A87	SANDERS, L. et al, "Controlled Release of a Luteinizing Hormone-Releasing Hormone Analogue from Poly(d, I-lactide-co-glycolide)Microspheres," <u>Journal of Pharmaceutical Sciences</u> , Vol. 73, pp. 1294-1297, September 1994	
A88	SATO, T. et al, "Porous Biodegradable Microspheres for Controlled Drug Delivery. I. Assessment of Processing Conditions and Solvent Removal Techniques," <u>Pharmaceutical Research</u> , Vol. 5, No. 1, pp. 21-30 January 1988	
A89	SCHMITT, E. et al., "Importance of Distinct Water Environments in the Hydrolysis of poly(DL-lactide-co-Glycolide," Macromolecules, 27:743-748, 1994	
A90	Supplemental Information Disclosure Statement, YAMAMOTO et al, Serial No. 858,040 filed 11/3/87 with the U.S. Patent and Trademark Office	
A91	The Pharmacopoeia of Japan, Tenth Edition, pp. 16- 21, 1981	
A92	WANG, H.T. et al., "Influence of formulation methods on the in vitro controlled release of protein from poly (ester) microspheres," <u>Journal of Controlled Release</u> 17:23-31, 1991	
A93	WOO, B. H. et al, "Preparation, characterization and in vivo evaluation of 120-day poly(D,L-lactide) Leuprolide microspheres," <u>Journal of Controlled Release</u> , 75:307-315, 2001	
	•	
	-	
	A86 A87 A88 A89 A90 A91 .	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. A86 PITT, C. et al, "Sustained Drug Delivery Systems, 1. The Permeability of Poly(e-Caprolactone), Poly(DL-Lactic Acid), and Their Copolymers," Journal of Biomedical Materials Research, Vol. 13, pp. 418-507, 1979 A87 SANDERS, L. et al, "Controlled Release of a Luteinizing Hormone-Releasing Hormone Analogue from Poly(d, I-lactide-co-glycolide)Microspheres," Journal of Pharmaceutical Sciences, Vol. 73, pp. 1294-1297, September 1994 A88 SATO, T. et al, "Porous Biodegradable Microspheres for Controlled Drug Delivery. I. Assessment of Processing Conditions and Solvent Removal Techniques," Pharmaceutical Research, Vol. 5, No. 1, pp. 21-30 January 1988 A89 SCHMITT, E. et al., "Importance of Distinct Water Environments in the Hydrolysis of poly(DL-lactide-co-Glycolide," Macromolecules, 27:743-748, 1994 A90 Supplemental Information Disclosure Statement, YAMAMOTO et al, Serial No. 858,040 filed 11/3/87 with the U.S. Patent and Trademark Office The Pharmacopoeia of Japan, Tenth Edition, pp. 16-21, 1981 A92 WANG, H.T. et al., "Influence of formulation methods on the in vitro controlled release of protein from poly (ester) microspheres," Journal of Controlled Release 17:23-31, 1991 A93 WOO, B. H. et al, "Preparation, characterization and in vivo evaluation of 120-day poly(D,L-lactide)

100		 Language and the second	
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.